An observational study in Postpartum Hemorrhage, sponsored by Havva Betül Bacak. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-08-11.
Sponsored by Havva Betül Bacak · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Postpartum Hemorrhage with a site in Turkey — 4 open to participants now, 5 under way, none of them phase 3. Postpartum Hemorrhage · Turkey.
Among the 45 studies in Postpartum Hemorrhage with a site in Turkey, this one is the 10th largest by enrollment of the 10 observational ones that give a count, is one of 2 that started in 2020, is one of 10 observational ones, and was the 34th registered.
471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.
Browse Postpartum Hemorrhage studies →4 of the 45 studies in Postpartum Hemorrhage with a site in Turkey are open now. Recruiting first, the newest first:
Mehmet Kırıköz · Sites in Turkey
Ages 24+ · Healthy volunteers
Saglik Bilimleri Universitesi Gulhane Tip Fakultesi · Sites in Turkey
Ages 18–35 · Women only · Healthy volunteers
Bagcilar Training and Research Hospital · Sites in Turkey
Ages 18–45 · Women only · Healthy volunteers
Cukurova University · Sites in Turkey
Ages 17–25 · Women only · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 169 across 96 observational studies indexed under Postpartum Hemorrhage.
Median enrollment 150 across the 35 interventional studies, 88 across the 10 observational. Of the 34 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 45 has an industry lead sponsor. The 10 most frequent:
Havva Betül Bacak is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Havva Betül Bacak has 1 study filed under Postpartum Hemorrhage — fewer than ten, so there is no comparison to draw.
1 of the studies in Postpartum Hemorrhage with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07943052Bagcilar Training and Research HospitalIntrauterine Misoprostol in Cesarean Delivery: Effect on Postpartum Hemorrhage | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 45 studies in Postpartum Hemorrhage with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This retrospective observational study aims to evaluate the efficacy and safety of Removable Uterine Compression Sutures (RUCS) in the surgical management of postpartum hemorrhage (PPH). Eleven patients who developed PPH and underwent RUCS between January 2020 and November 2024 at Gaziosmanpaşa Training and Research Hospital were included. The primary outcomes assessed were hemorrhage control and procedure-related complications. Data were collected from patient records and analyzed descriptively.
Postpartum hemorrhage (PPH) remains one of the leading causes of maternal morbidity and mortality worldwide. When medical management is insufficient, surgical interventions become necessary. Removable Uterine Compression Sutures (RUCS) have been developed as a uterus-sparing surgical technique that may offer effective hemostasis with a potentially lower risk of complications such as intrauterine synechiae, when compared to traditional permanent suture methods.
This single-center retrospective observational case series evaluated 11 patients who experienced PPH and were treated with RUCS at the Obstetrics and Gynecology Clinic of Gaziosmanpaşa Training and Research Hospital between January 2020 and November 2024. Patients were included if they had complete medical records and underwent RUCS after delivery. Cases involving other surgical techniques or missing data were excluded.
Clinical data were extracted from hospital archives and electronic medical systems. All data were anonymized prior to analysis. Descriptive statistics were used, including means and standard deviations for continuous variables and frequencies for categorical variables.
The study aimed to assess both the efficacy of RUCS in controlling bleeding and its safety by monitoring postoperative complications such as intrauterine synechiae and uterine necrosis. Initial findings indicate 100% success in hemostasis with no observed major complications, suggesting that RUCS may be a safe and effective option in selected cases of postpartum hemorrhage.
The study population consists of women aged 18-45 who developed postpartum hemorrhage following delivery and were treated with Removable Uterine Compression Sutures (RUCS) at Gaziosmanpaşa Training and Research Hospital between January 2020 and November 2024. Only patients with complete and accessible medical records were included in this retrospective case series.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female patients aged 18 to 45 years Diagnosed with postpartum hemorrhage (PPH) following delivery Treated with Removable Uterine Compression Suture (RUCS) Delivery and treatment performed at Gaziosmanpaşa Training and Research Hospital RUCS performed between January 2020 and November 2024 Complete and accessible medical records
Exclusion Criteria:
Incomplete or missing medical records Use of alternative surgical techniques other than RUCS Patients outside the age range of 18-45 Cases not treated at Gaziosmanpaşa Training and Research Hospital Postpartum hemorrhage not managed with RUCS
This group includes women aged 18-45 who experienced postpartum hemorrhage and were treated with Removable Uterine Compression Sutures (RUCS) at Gaziosmanpaşa Training and Research Hospital between January 2020 and November 2024. All patients had complete medical records and underwent retrospective data analysis.
Procedure: Removable Uterine Compression Suture (RUCS)
Removable Uterine Compression Suture (RUCS) is a uterus-preserving surgical technique used to control postpartum hemorrhage (PPH) when medical management fails. The suture is placed in a way that allows for its removal after hemostasis is achieved, potentially reducing the risk of complications such as intrauterine synechiae. In this study, RUCS was applied to 11 patients following delivery-related hemorrhage.
Hemostasis success rate following RUCS application
Successful control of postpartum bleeding without the need for additional surgical intervention, blood transfusion exceeding 4 units, or hysterectomy.
Time frame: Within the first 24 hours post-procedure
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2020 to primary completion in Nov 2024, 58 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Havva Betül Bacak